Obi Greenman
Chief Executive Officer chez CERUS CORPORATION
Fortune : 6 M $ au 31/03/2024
Profil
William Mariner Greenman is currently the President, Chief Executive Officer & Director at Cerus Corp.
He previously served as an Independent Director at Aduro BioTech, Inc. and Chinook Therapeutics, Inc. He also held the position of Senior Vice President-Biotech Division at Baxter International, Inc. Mr. Greenman obtained his undergraduate degree from Stanford University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CERUS CORPORATION
1,75% | 14/03/2024 | 3 181 281 ( 1,75% ) | 6 M $ | 31/03/2024 |
Postes actifs de Obi Greenman
| Sociétés | Poste | Début |
|---|---|---|
| CERUS CORPORATION | Chief Executive Officer | 21/04/2011 |
Anciens postes connus de Obi Greenman
| Sociétés | Poste | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 11/08/2023 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01/01/1995 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | - |
Formation de Obi Greenman
| Stanford University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CERUS CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
